Subjects:
BloodWork, Free Research Articles, Myeloid Neoplasia
Topics:
karyotype determination procedure, leukemia, myelocytic, acute, mast cells, myelodysplastic syndrome, preleukemia
A 43-year-old woman was admitted due to a 6-week history of asthenia. She was pale; no other findings were observed in the physical exam. Blood count was 2.4 × 109/L, (56N, 33L, 9M, 1Eo), hemoglobin was 69 g/L, and platelet count was 15 × 109/L; 3% blast cells were counted in peripheral blood. A bone marrow aspirate showed 30% myeloperoxidase-positive blast cells, 20% erythroid cells, and 27% of semimature and mature neutrophilic myeloid cells. Dysplasia (>20%) was observed in all 3 myeloid cell lines. No mast cells were noted. She had the following karyotype: 46,XX [6]/ 44,XX,del(5)(q31), −9, −11, −12, −13, −16, −19, +4mar [21]. / The patient did not reached hematologic response with either idarubicin/AraC (3/7) or FLAG-idarubicin schedules. Another bone marrow aspirate performed 6 weeks after the latter chemotherapy showed 12% myeloblasts. In addition, a number of hypergranular giant multilobated cells were observed (panel A). Immunocytochemistry stains (alkaline phosphatase anti–alkaline phosphatase) with CD117 (panel B) and CD25 (panel C) were positive, but CD2 was negative. Immunostain with tryptase was positive (panel D). Sanger sequencing of c-kit exons 8 and 17 ruled out mutations. We herein show atypical mastocytic cells in the setting of an evolved acute myeloid leukemia, although not fulfilling the criteria for myelomastocytic leukemia.
View largeDownload PPT

A 43-year-old woman was admitted due to a 6-week history of asthenia. She was pale; no other findings were observed in the physical exam. Blood count was 2.4 × 109/L, (56N, 33L, 9M, 1Eo), hemoglobin was 69 g/L, and platelet count was 15 × 109/L; 3% blast cells were counted in peripheral blood. A bone marrow aspirate showed 30% myeloperoxidase-positive blast cells, 20% erythroid cells, and 27% of semimature and mature neutrophilic myeloid cells. Dysplasia (>20%) was observed in all 3 myeloid cell lines. No mast cells were noted. She had the following karyotype: 46,XX [6]/ 44,XX,del(5)(q31), −9, −11, −12, −13, −16, −19, +4mar [21].

The patient did not reached hematologic response with either idarubicin/AraC (3/7) or FLAG-idarubicin schedules. Another bone marrow aspirate performed 6 weeks after the latter chemotherapy showed 12% myeloblasts. In addition, a number of hypergranular giant multilobated cells were observed (panel A). Immunocytochemistry stains (alkaline phosphatase anti–alkaline phosphatase) with CD117 (panel B) and CD25 (panel C) were positive, but CD2 was negative. Immunostain with tryptase was positive (panel D). Sanger sequencing of c-kit exons 8 and 17 ruled out mutations. We herein show atypical mastocytic cells in the setting of an evolved acute myeloid leukemia, although not fulfilling the criteria for myelomastocytic leukemia.

A 43-year-old woman was admitted due to a 6-week history of asthenia. She was pale; no other findings were observed in the physical exam. Blood count was 2.4 × 109/L, (56N, 33L, 9M, 1Eo), hemoglobin was 69 g/L, and platelet count was 15 × 109/L; 3% blast cells were counted in peripheral blood. A bone marrow aspirate showed 30% myeloperoxidase-positive blast cells, 20% erythroid cells, and 27% of semimature and mature neutrophilic myeloid cells. Dysplasia (>20%) was observed in all 3 myeloid cell lines. No mast cells were noted. She had the following karyotype: 46,XX [6]/ 44,XX,del(5)(q31), −9, −11, −12, −13, −16, −19, +4mar [21]. / The patient did not reached hematologic response with either idarubicin/AraC (3/7) or FLAG-idarubicin schedules. Another bone marrow aspirate performed 6 weeks after the latter chemotherapy showed 12% myeloblasts. In addition, a number of hypergranular giant multilobated cells were observed (panel A). Immunocytochemistry stains (alkaline phosphatase anti–alkaline phosphatase) with CD117 (panel B) and CD25 (panel C) were positive, but CD2 was negative. Immunostain with tryptase was positive (panel D). Sanger sequencing of c-kit exons 8 and 17 ruled out mutations. We herein show atypical mastocytic cells in the setting of an evolved acute myeloid leukemia, although not fulfilling the criteria for myelomastocytic leukemia.
View largeDownload PPT

A 43-year-old woman was admitted due to a 6-week history of asthenia. She was pale; no other findings were observed in the physical exam. Blood count was 2.4 × 109/L, (56N, 33L, 9M, 1Eo), hemoglobin was 69 g/L, and platelet count was 15 × 109/L; 3% blast cells were counted in peripheral blood. A bone marrow aspirate showed 30% myeloperoxidase-positive blast cells, 20% erythroid cells, and 27% of semimature and mature neutrophilic myeloid cells. Dysplasia (>20%) was observed in all 3 myeloid cell lines. No mast cells were noted. She had the following karyotype: 46,XX [6]/ 44,XX,del(5)(q31), −9, −11, −12, −13, −16, −19, +4mar [21].

The patient did not reached hematologic response with either idarubicin/AraC (3/7) or FLAG-idarubicin schedules. Another bone marrow aspirate performed 6 weeks after the latter chemotherapy showed 12% myeloblasts. In addition, a number of hypergranular giant multilobated cells were observed (panel A). Immunocytochemistry stains (alkaline phosphatase anti–alkaline phosphatase) with CD117 (panel B) and CD25 (panel C) were positive, but CD2 was negative. Immunostain with tryptase was positive (panel D). Sanger sequencing of c-kit exons 8 and 17 ruled out mutations. We herein show atypical mastocytic cells in the setting of an evolved acute myeloid leukemia, although not fulfilling the criteria for myelomastocytic leukemia.

Close modal

For additional images, visit the ASH IMAGE BANK, a reference and teaching tool that is continually updated with new atlas and case study images. For more information visit http://imagebank.hematology.org.

© 2014 by The American Society of Hematology
2014
Sign in via your Institution